Gujarat Inject Share Price Today | Stock Price & Gujarat Inject Share Screener
As of October 5, 2026, the live Gujarat Inject share price (BSE: GUJINJEC) is ₹9.09, down 0.98% from the previous close, with shares trading between ₹8.77 and ₹9.18 in today's trading session, and a 52-week range of ₹9.08–₹130.90. Check Gujarat Inject yearly highs lows for the annual price range and momentum. Use the Gujarat Inject stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gujarat Inject opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹12 and net income of ₹1, with EBITDA of ₹1, an operating margin of 4.0% and a profit margin of 8.3%.
Gujarat Inject Share Price Chart
Track the current stock price of Gujarat Inject with an interactive chart. Analyse GUJINJEC share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gujarat Inject stock quote in one place.
The quote of ₹9.09 sits between the 52-week low of ₹9.08 and the 52-week high of ₹130.90, and the latest session moved -0.98% from the previous close.
Gujarat Inject Company Profile - Fundamental Screener
Screen Gujarat Inject company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUJINJEC shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE659F01014.
Company Details
Classification
Identifiers and Leadership
Gujarat Inject Balance Sheet Screener
Screen GUJINJEC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹12 against total liabilities of ₹12, up from ₹9 in 2024.
Latest statistics put total assets at ₹12 and shareholder funds at ₹10, with a leverage ratio of 0.08.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 12 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 9 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liabilities |
||||||||||
| Total Liabilities | 12 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 10 | 9 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Share Capital | 15 | 11 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -5 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 |
Gujarat Inject Income Statement Screener - Profit & Revenue Analysis
Screen Gujarat Inject income statement and profit fundamentals. Analyze GUJINJEC quarterly results. Gujarat Inject reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹12 and net profit was ₹1, equal to earnings per unit of ₹0.30, at an operating margin of 4%.
In that period expenses were ₹11, interest cost ₹0 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹19 and net profit of ₹1.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 12 | 19 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Expenses | 11 | 18 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Operating Costs and Margins | ||||||||||||
| EBITDA | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | 4.00% | 6.00% | 1.00% | -217.00% | -200.00% | -982.00% | 0.00% | 0.00% | 0.00% | 1.00% | 4.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.30 | 0.70 | 0.09 | 0.05 | 0.00 | -0.12 | 0.00 | -0.01 | -0.03 | 0.02 | 4.70 | -0.01 |
Gujarat Inject Cash Flow Screener - Liquidity Fundamentals
Screen GUJINJEC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2024-March, operating activities used ₹6, and net cash flow was an inflow of ₹3.
Over the same period, investing activities provided ₹0 and financing activities provided ₹9.
| Item | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gujarat Inject Shareholding Pattern Screener
See Gujarat Inject shareholding pattern with promoter, FII, and DII holdings. Check Gujarat Inject promoter holding and ownership changes for GUJINJEC on TickJournal, and see how institutional stock price moves affect the market.
In 2025-Mar, promoters held 0.00%, foreign institutions 0.00%, domestic institutions 0.00% and the public 83.95%, spread across 7,303 shareholders.
The shareholder count was 7,303 in 2025-Mar, compared with 7,303 in 2025-Jun.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Apr | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 83.95% | 83.95% | 92.83% | 88.24% | 86.82% | 86.79% | 86.80% | 85.91% |
| Other Holding | 16.05% | 16.05% | 7.17% | 11.75% | 13.18% | 13.21% | 13.20% | 14.08% |
| Shareholder Count | 7,303 | 7,303 | 8,151 | 6,721 | 6,706 | 6,698 | 6,627 | 6,773 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gujarat Inject. Gujarat Inject dividend yield can be compared with peers and other stocks in the market.
Gujarat Inject Stock Index Membership - Nifty & Sensex
See which indices include Gujarat Inject stock. Check GUJINJEC index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Gujarat Inject Market Events Screener - Corporate Actions
Get Gujarat Inject corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gujarat Inject stock events that may affect GUJINJEC share price, along with derivatives, futures and options activity and sector gainers.
10 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 13, 2025, with a record date of November 13, 2025.
It is followed by Annual General Meeting dated September 30, 2025 and Quarterly Result Announcement dated August 14, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 2.08% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -0.40% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 1.33% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 3.73% |
| 2025-04-03 | 2025-04-03 | Extraordinary General Meeting | NA | 0.15% |
| 2025-02-18 | 2025-02-18 | Change Of Name | NA | 0.00% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -0.08% |
| 2024-10-22 | 2024-10-22 | Quarterly Result Announcement | NA | -4.95% |
| 2024-09-28 | 2024-09-28 | Annual General Meeting | NA | 0.00% |
| 2024-01-20 | 2024-01-20 | Extraordinary General Meeting | NA | 10.00% |
Gujarat Inject Competitors Screener - Peer Stocks Comparison
Screen GUJINJEC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Gujarat Inject Company Announcements - News & Reports Screener
Screen GUJINJEC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 26, 2026.
The next most recent announcements are dated December 9, 2025 and November 13, 2025.
| Date | Update | Actions |
|---|---|---|
| 2026-09-26 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2025-11-13 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday 13Th November 2025 | - |
| 2025-11-13 | UNAUDITED FINANCIAL RESULTS AS ON 30.09.2025. | - |
| 2025-11-10 | Board Meeting Intimation for Un-Audited Financial Results (Standalone) Of The Company For The Quarter And Half Year Ended On 30Th September 2025 Along With Limited Review Report Of The Statutory Auditors Thereon; | - |
| 2025-10-30 | Board Meeting Outcome for Outcome Of Board Meeting Dated Thursday 30Th October 2025 | - |
| 2025-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2025-10-01 | Closure of Trading Window | - |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2025-09-10 | Reg. 34 (1) Annual Report. | - |
| 2025-09-10 | Notice Of 34Th Annual General Meeting Along With Annual Report Of The Company For F.Y. 2024-25. | - |
| 2025-09-08 | Board Meeting Outcome for Change Of Object Of The Company. | - |
| 2025-08-14 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday 14Th August 2025 | - |
| 2025-08-14 | FINANCIAL RESULTS 30.06.2025 | - |
| 2025-08-11 | Board Meeting Intimation for Approval Of Un-Audited Financial Results Of The Company For The Quarter Ended On 30Th June 2025 | - |
| 2025-07-25 | Revised Outcome Of The Board Meeting Held On 07Th July 2025 | - |
| 2025-07-15 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2025-07-07 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2025-07-07 | Board Meeting Outcome for Outcome Of Board Meeting Dated 07Th July 2025 | - |
| 2025-07-01 | Closure of Trading Window | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹9.09, within a 52-week range of ₹9.08 to ₹130.90. The P/E ratio is 15.00 and the P/B ratio is 4.75, with earnings per unit of ₹0.70. Market capitalisation stands at ₹48.99 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.